Talis Biomedical Corporation (TLIS) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Devices secteur d'activité. Le siège social de l'entreprise est situé à Menlo Park, CA, United States. Le PDG actuel est Rebecca Markovich.
TLIS a date d'introduction en bourse 2021-02-12, 99 employés à temps plein, cotée sur le Other OTC, une capitalisation boursière de $5.18M.
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
